INHIBITORS OF COMPLEMENT FACTOR C3 AND THEIR MEDICAL USES

Compstatin analogues having improved physicochemical properties, such as increased stability and/or solubility as compared to the 13 amino acid compstatin peptide are described, in particular compstatin analogues that additionally possess useful binding and complement- inhibiting activity. These ana...

Full description

Saved in:
Bibliographic Details
Main Authors LETH, Rasmus, SHELTON, Anne Pernille Tofteng, MUNCH, Henrik Fischer
Format Patent
LanguageEnglish
French
Published 20.01.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Compstatin analogues having improved physicochemical properties, such as increased stability and/or solubility as compared to the 13 amino acid compstatin peptide are described, in particular compstatin analogues that additionally possess useful binding and complement- inhibiting activity. These analogues have an alkylene bridge between sulphur atoms of cysteine residues and include variants with an isoleucine residue at position 3 in place of the wild type valine residue, which provides compstatin peptides with improved binding and complement- inhibiting activity and also enables the introduction of other modifications, for example modifications that are capable of increasing stability, such as the introduction of lysine or serine at position 11. L'invention concerne des analogues de compstatine ayant des propriétés physicochimiques améliorées, telles qu'une stabilité et/ou une solubilité accrues par rapport au peptide de compstatine de 13 acides aminés, en particulier des analogues de compstatine qui possèdent en outre une activité utile de liaison et d'inhibition du complément. Ces analogues ont un pont alkylène entre les atomes de soufre des résidus cystéine et comprennent des variants ayant un résidu isoleucine en position 3 à la place du résidu valine de type sauvage, qui fournit des peptides de compstatine ayant une activité de liaison et d'inhibition du complément améliorée et permet également l'introduction d'autres modifications, par exemple des modifications qui sont capables d'augmenter la stabilité, telle que l'introduction de lysine ou de sérine en position 11.
Bibliography:Application Number: WO2021EP69798